North America Peptide And Oligonucleotide Cdmo Market Size & Outlook

The peptide and oligonucleotide cdmo market in North America is expected to reach a projected revenue of US$ 1,928.0 million by 2030. A compound annual growth rate of 11.5% is expected of North America peptide and oligonucleotide cdmo market from 2024 to 2030.
Revenue, 2023 (US$M)
$897.1
Forecast, 2030 (US$M)
$1,928.0
CAGR, 2024 - 2030
11.5%
Report Coverage
North America

North America peptide and oligonucleotide cdmo market, 2018-2030 (US$M)

North

Related Markets

North America peptide and oligonucleotide cdmo market highlights

  • The North America peptide and oligonucleotide cdmo market generated a revenue of USD 897.1 million in 2023.
  • The market is expected to grow at a CAGR of 11.5% from 2024 to 2030.
  • In terms of segment, peptides was the largest revenue generating product in 2023.
  • Oligonucleotides is the most lucrative product segment registering the fastest growth during the forecast period.
  • Country-wise, U.S. is expected to register the highest CAGR from 2024 to 2030.


North America data book summary

Market revenue in 2023USD 897.1 million
Market revenue in 2030USD 1,928.0 million
Growth rate11.5% (CAGR from 2023 to 2030)
Largest segmentPeptides
Fastest growing segmentOligonucleotides
Historical data covered2018 - 2022
Base year for estimation2023
Forecast period covered2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPeptides, Oligonucleotides
Key market players worldwidePolyPeptide Group AG, Wuxi AppTec Co Ltd, Bachem Holding AG, Dr Reddy's Laboratories Ltd ADR, Merck KGaA, Euroapi SA, SYLENTIS, CordenPharma, Curia, Creative Peptides


Other key industry trends

  • In terms of revenue, North America region accounted for 35.4% of the global peptide and oligonucleotide cdmo market in 2023.
  • Globally, Europe is projected to lead the regional market in terms of revenue in 2030.
  • Asia Pacific is the fastest growing regional market and is projected to reach USD 1,230.5 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Peptide And Oligonucleotide CDMO Market Companies

Name Profile # Employees HQ Website

North America peptide and oligonucleotide cdmo market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide and oligonucleotide cdmo market will help companies and investors design strategic landscapes.


Peptides was the largest segment with a revenue share of 66.26% in 2023. Horizon Databook has segmented the North America peptide and oligonucleotide cdmo market based on peptides, oligonucleotides covering the revenue growth of each sub-segment from 2018 to 2030.


Reasons to subscribe to North America peptide and oligonucleotide cdmo market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of North America peptide and oligonucleotide cdmo market databook

  • Our clientele includes a mix of peptide and oligonucleotide cdmo market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of continent-level data and insights on the North America peptide and oligonucleotide cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into North America peptide and oligonucleotide cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

North America peptide and oligonucleotide cdmo market size, by country, 2018-2030 (US$M)

North America Peptide And Oligonucleotide CDMO Market Outlook Share, 2023 & 2030 (US$M)

North America peptide and oligonucleotide cdmo market size, by country, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more